• Username (E-mail)
  • Password
Dow 19,800 -0.1%  EStoxx50 3,281 0.2%  Nikkei 18,788 -0.6%  EUR 1.0731 -0.3% 
Nasdaq 5,553 0.0%  FTSE100 7,172 0.3%  Yen 113.3740 0.7%  Oil 55.4 0.0% 
S&P500 2,265 -0.3%  DAX 11,577 0.3%  GBP 1.2448 -0.7%  Gold 1,212 -0.6% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

11/05/2012 08:11:52 AM
11/05/2012 08:11:52 AM UTC-0500

Vertex Pharmaceuticals Inc. Sell

The analysts of Goldman Sachs Group Inc. have rated Vertex Pharmaceuticals with a Sell rating. The price target was set to 43.00 $. At a current price of the Vertex Pharmaceuticals stock of 81.42 $ this means a downside potential of -47.19%.
Summary: Vertex Pharmaceuticals Inc. Sell
Company:
Vertex Pharmaceuticals Inc.
Analyst:
Goldman Sachs Group Inc.
Price Target:
43.00 $
Current Rating:
Sell
Price*:
46.41 $
Distance to Target Price*:
-7.35%
Previous Rating:
Downgrade
Latest Price:
81.42 $
Distance Price Target:
-47.19%
Analyst Name::
Terence Flynn
P/E Ratio*:
-

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/14/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
12/05/12
Vertex Pharmaceuticals RBC Capital Markets
11/13/12
Vertex Pharmaceuticals Credit Suisse Group
11/05/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
11/02/12
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Latest Analyst Opinions
01/23/17 TLG IMMOBILIEN Norddeutsche Landesbank (Nord/LB)
01/23/17 ABB JP Morgan Chase & Co.
01/23/17 Zurich Insurance Group JP Morgan Chase & Co.
01/23/17 Apple Bernstein Research
01/23/17 Novo Nordisk A-S (B) JP Morgan Chase & Co.
01/23/17 Sky UBS AG
01/23/17 Vodafone Group UBS AG
01/23/17 BT Group UBS AG
01/23/17 RHÖN-KLINIKUM Independent Research GmbH
01/23/17 Credit Suisse Morgan Stanley
01/23/17 Deutsche Bank Morgan Stanley
01/23/17 Intesa Sanpaolo JP Morgan Chase & Co.
01/23/17 HORNBACH Baumarkt Hauck & Aufhäuser Privatbankiers KGaA
01/23/17 RHÖN-KLINIKUM Commerzbank AG
01/23/17 NORMA Group Oddo Seydler Bank AG
01/23/17 Reckitt Benckiser Group Barclays Capital
01/23/17 Deutsche Bank Commerzbank AG
01/23/17 LOréal Barclays Capital
01/23/17 Diageo Barclays Capital
01/23/17 LVMH Moet Hennessy Louis Vuitton Deutsche Bank AG
01/23/17 Renault UBS AG
01/23/17 Continental UBS AG
01/23/17 Daimler UBS AG
01/23/17 adidas Deutsche Bank AG
01/23/17 AstraZeneca Deutsche Bank AG
01/23/17 CompuGroup Medical Baader Bank
01/23/17 Bechtle Baader Bank
01/23/17 Beiersdorf Barclays Capital
01/23/17 Henkel vz Barclays Capital
01/23/17 Unilever Barclays Capital
01/23/17 Unilever Barclays Capital
01/23/17 GlaxoSmithKline Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
01/23/17 Orange Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
01/23/17 BNP Paribas Deutsche Bank AG
01/23/17 Société Générale SA Deutsche Bank AG
01/23/17 zooplus Warburg Research
01/23/17 ASML Baader Bank
01/23/17 Novo Nordisk A-S (B) Kepler Cheuvreux
01/23/17 Vonovia Kepler Cheuvreux
01/23/17 AIXTRON Baader Bank
01/23/17 Anheuser-Busch InBev UBS AG
01/23/17 PUMA Deutsche Bank AG
01/23/17 Glencore UBS AG
01/23/17 BT Group UBS AG
01/23/17 Royal Dutch Shell (A) UBS AG
01/23/17 Eni UBS AG
01/23/17 LOréal UBS AG
01/23/17 PUMA JP Morgan Chase & Co.
01/23/17 Novo Nordisk A-S (B) Goldman Sachs Group Inc.
01/23/17 Hapag-Lloyd Aktiengesellschaft Goldman Sachs Group Inc.